WINNIPEG, MANITOBA -- (MARKET WIRE) -- May 28, 2007 -- Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products is pleased to announce the final results from its PCSC04 study.
